<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">YENCILEK, FARUK</style></author><author><style face="normal" font="default" size="100%">YILMAZ, SEDA GULEC</style></author><author><style face="normal" font="default" size="100%">YILDIRIM, ASIF</style></author><author><style face="normal" font="default" size="100%">GORMUS, UZAY</style></author><author><style face="normal" font="default" size="100%">ALTINKILIC, EMRE MURAT</style></author><author><style face="normal" font="default" size="100%">DALAN, ALTAY BURAK</style></author><author><style face="normal" font="default" size="100%">BASTUG, YAVUZ</style></author><author><style face="normal" font="default" size="100%">TURKMEN, SELDA</style></author><author><style face="normal" font="default" size="100%">TURKAN, SADI</style></author><author><style face="normal" font="default" size="100%">ISBIR, TURGAY</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Apolipoprotein E Genotypes in Patients with Prostate Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">707-711</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Apolipoprotein E (ApoE) is a potential inhibitor of cell proliferation, immune regulation and modulation of cell growth and differentiation; it also has a substantial role in antioxidant activity. ApoE has a potential role in prostate cancer progression. Materials and Methods: ApoE genotyping was performed using real-time polymerase chain reaction (RT-PCR) for blood samples from a group of patients with prostate cancer (n=68) and a control group (n=78). Results: The frequency of the E3/E3 genotype was significantly higher in patients compared to controls (p=0.004). E3/E3 genotype carriers were 3.6-fold more likely to be patients than controls (odds ratio=3.67, 95% confidence interval=1.451-9.155; p=0.004). Additionally, the patients with E3/E3 genotype had significantly higher Gleason score (p=0.017), and more patients with this genotype had a Gleason score higher than 7 (p=0.007). Individuals carrying the E4 allele were significantly more common in the control group (p=0.006). The frequency of the E3/E4 genotype was found to be significantly higher in controls compared to patients (p=0.007), and patients were significantly less likely to have this genotype than controls (odds ratio=0.89, 95% confidence interval=0.833-0.967, p=0.007). Individuals carrying the E2/E3 genotype had a significantly lower Gleason score (p=0.049)–all of the patients with this genotype had a Gleason score lower than 7 (p=0.024). Conclusion: E3/E3 genotype may be a potential risk factor for prostate cancer and high Gleason scoring. The E4 allele maybe a risk-reducing factor for prostate cancer.</style></abstract></record></records></xml>